Captopril in cardiological patients treatment: is there still place for the “first of the Mohicans”?
- Authors: Valikulova F.Y.1, Koroleva L.Y.1, Melnichenko O.V.1, Duryndina E.M.1, Muradova F.N.1, Alekseeva M.M.1
-
Affiliations:
- Privolzhsky Research Medical University of the Ministry of Health of the Russian Federation
- Issue: Vol 21, No 1 (2019)
- Pages: 92-96
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/96908
- DOI: https://doi.org/10.26442/20751753.2019.1.190298
- ID: 96908
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Farogat Yu. Valikulova
Privolzhsky Research Medical University of the Ministry of Health of the Russian Federation
Email: mumtos1951@list.ru
Cand. Sci. (Med.), Assistant Professor at Department of Internal Medicine 10/1, Minin and Pozharsky sq., Nizhny Novgorod, 603000, Russian Federation
Liubov Yu. Koroleva
Privolzhsky Research Medical University of the Ministry of Health of the Russian FederationCand. Sci. (Med.), Assistant Professor 10/1, Minin and Pozharsky sq., Nizhny Novgorod, 603000, Russian Federation
Olesia V. Melnichenko
Privolzhsky Research Medical University of the Ministry of Health of the Russian FederationCand. Sci. (Med.), Assistant Professor 10/1, Minin and Pozharsky sq., Nizhny Novgorod, 603000, Russian Federation
Elena M. Duryndina
Privolzhsky Research Medical University of the Ministry of Health of the Russian FederationCand. Sci. (Med.), Assistant Professor 10/1, Minin and Pozharsky sq., Nizhny Novgorod, 603000, Russian Federation
Fazliniso N. Muradova
Privolzhsky Research Medical University of the Ministry of Health of the Russian Federationstudent 10/1, Minin and Pozharsky sq., Nizhny Novgorod, 603000, Russian Federation
Mariia M. Alekseeva
Privolzhsky Research Medical University of the Ministry of Health of the Russian Federationstudent 10/1, Minin and Pozharsky sq., Nizhny Novgorod, 603000, Russian Federation
References
- Cushman D.W, Ondetti M.A. History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension 1991; 17: 589-92.
- Smith C.G, Vane J.R. The discovery of captopril. FASEB Jounal 2003; 17: 788-9.
- Zanchetti A, Mancia G. Longing for clinical excellence: a critical outlook into the NICE recommendations on hypertension management: is nice always good? J Hypertens 2012; 30: 660-8.
- Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019; 16 (1): 6-31. doi: 10.26442/2075082X.2019.1.190179
- Терпигорев С.А., Никишенков А.М., Кабанова Т.Г. и др. Применение каптоприла в лечении сердечно-сосудистых заболеваний. Consilium Medicum. 2018; 20 (1): 21-6.
- Hansson L, Lindholm L.H et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-6.
- Приказ Минздрава России №549н от 07.08.2013 «Об утверждении требований к комплектации лекарственными препаратами и медицинскими изделиями укладок и наборов для оказания скорой медицинской помощи».
- Mansoor G.A, Frishman W.H. Comprehensive management of hypertensive emergencies and urgencies. Heart Dis 2002; 4: 358-71.
- Мареев В.Ю., Фомин И.В. Клинические рекомендации ОССН - РКО - РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018; 58 (S6).
- Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273 (18): 1450-6.
- Мареев В.Ю., Даниелян М.О., Беленков Ю.Н. Влияние терапии на прогноз и выживаемость больных с хронической сердечной недостаточностью. Рус. мед. журн. 1999; 2: 9.
- Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-77.
- Pitt B, Poole-Wilson P.A, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-7.
- Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360 (9335): 752-60.
- Fox K.M. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebocontrolled, multicentre trial (the EUROPA study). Lancet 2003; 362 (9386): 782-8.
- Pfeffer M.A, McMurray J.J.V, Velazquez E.J et al. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. N Engl J Med 2003; 349 (20): 1893-906. doi: 10.1056/NEJMoa032292
- Progress. Effects of a Perindopril-Based Blood Pressure-Lowering Regimen on Disability and Dependency in 6105 Patients With Cerebrovascular Disease: A Randomized Controlled Trial. Stroke 2003; 34 (10): 2333-8. DOI:10.1161 / 01. STR. 0000091397.81767.40